Evidence map›Paper›PMID 35530278›Full record

ReviewAmerican journal of cancer research2022

Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.

Parham Jabbarzadeh Kaboli, Shima Shabani, Sagar Sharma, Minoo Partovi Nasr, Hirohito Yamaguchi, Mien-Chie Hung

Open access · greenAbstract readReview
PubMed Full text at PMC
In one paragraph

Review in American journal of cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
3.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. ImmunoPET imaging of Trop2 expression in triple-negative breast cancer using [European journal of nuclear medicine and molecular imaging · 2025
    Article
  15. Review
  16. TROP2-targeted molecular imaging: a promising tool for precision oncology.American journal of nuclear medicine and molecular imaging · 2025
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 3 countries.

Parham Jabbarzadeh KaboliGraduate Institute of Biomedical Sciences, China Medical University Taichung, Taiwan.
Shima ShabaniDepartment of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University P.O. Box 14115/111, Tehran, Iran.
Sagar SharmaInstitute of Biology, Biotechnology, and Environmental Protection, Faculty of Natural Sciences, University of Silesia in Katowice 40-032 Katowice, Poland.
Minoo Partovi NasrDepartment of Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB) Tehran, Iran.
Hirohito YamaguchiGraduate Institute of Biomedical Sciences, China Medical University Taichung, Taiwan.
Mien-Chie HungGraduate Institute of Biomedical Sciences, China Medical University Taichung, Taiwan.
China Medical University · TWAsia University · TWNational Institute of Genetic Engineering and Biotechnology · IRTarbiat Modares University · IRUniversity of Silesia in Katowice · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is well-known as the most aggressive subtype of breast cancer. Because TNBC does not express Her2, estrogen receptor, and progesterone receptors, there had been no effective U.S. Food and Drug Administration-approved targeted therapy for it until PARP inhibitors and two PD-1/PD-L1 monoclonal antibodies were approved for treatment of TNBC. Most recently, an antibody-drug conjugate (ADC), called sacituzumab govitecan (SG), was approved for the treatment of TNBC patients previously received chemotherapy with advanced disease. SG consists of an anti-trophoblast cell-surface antigen 2 (Trop2) antibody conjugated with a topoisomerase I inhibitor, SN-38, which is diffused out of the targeted Trop2 positive cancer cells and induces the bystander killing effect on surrounding cells regardless of their Trop2 expression status. In the Phase III clinical trial, TNBC patients treated with SG showed significantly longer progression-free and overall survival compared to those who were received chemotherapy. In the present review, we summarized the cellular function and signaling of Trop2, the mechanism of action of SG, and the clinical trials of SG that led to its quick approval for TNBC. In addition, we introduced the current ongoing clinical trials of SG as well as another Trop2 ADC, which has potential to overcome some disadvantages of SG.

Indexed as

antibody-drug conjugatessacituzumab govitecanSN-38Triple-negative breast cancerTrop2

Identifiers

PMID35530278
PMCPMC9077081
OpenAlexW4285741464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.